Grading the quality of evidence and the strength of recommendations Equity.

Slides:



Advertisements
Similar presentations
Evidence Based Practice MMR Vaccine Who Has Concerns About the Safety of This Vaccine?
Advertisements

How can we improve the quality of Cochrane Reviews (in 8 minutes)? David Tovey.
Conclusion Epidemiology and what matters most
Tobacco control and the new structures for public health Professor Kevin Fenton Director of Health & Wellbeing Twitter:
Decision Criteria and Process Advisory Committee on Heritable Disorders in Newborns and Children February 26-27, 2009.
Scottish Intercollegiate Guidelines Network (SIGN)
The National Comprehensive Cancer Control Program (NCCCP): Current Progress and Future Action Temeika L. Fairley, Epidemiologist Comprehensive Cancer Control.
Hospitality - Practical Cake Craft CPD Presentation.
Public Health Perspective on Radon Control in Ireland Dr. Ina Kelly Specialist Registrar in Public Health Medicine Health Service Executive Department.
Summarising findings about the likely impacts of options Judgements about the quality of evidence Preparing summary of findings tables Plain language summaries.
Incorporating considerations about equity in policy briefs What factors are likely to be associated with disadvantage? Are there plausible reasons for.
Pneumonia Sapna Bamrah, MD CDC
Health Equity 101 An Introduction to Health Equity June 26, 2013.
Grading of Recommendations Assessment, Development and Evaluation (GRADE) Methodology.
Guidelines and Guideline Development HINF Medical Methodologies Session 13.
Cancer Program Standards 2012: Ensuring Patient-Centered Care
Higher Physical Education
Discussion Gitanjali Batmanabane MD PhD. Do you look like this?
Commissioning for Culture, Health and Wellbeing Ian Tearle Head of Health Policy Directorate of Public Health, NHS Devon Wednesday 7 th March 2012.
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
What it is?  It’s a lung disease involving inflammation  Before the development of antibiotic drugs in the 1940’s, this disease killed 1/3 of its victims.
Value of Information Analysis Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center Los Angeles Biomedical Research Institute.
HSC PDHPE Cancer The Cancer Council NSW Carla Saunders Medical and Scientific Policy Manager The Cancer Council NSW
BIOE 301 Lecture Seventeen. Guest Speaker Jay Brollier World Camp Malawi.
General lessons and principles about where to concentrate efforts on reducing inequalities in health Sally Macintyre.
Inequalities in Health Work-related policies and interventions.
Health Disparities Affecting Minorities African Americans.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
This article and any supplementary material should be cited as follows: Littman AJ, Koepsell TD, Forsberg CW, Haselkorn JK, Boyko EJ. Preventive services.
University of Iowa Cancer Prevention and Control Research Network Sue Curry, Ph.D., Principal Investigator This presentation was supported by Cooperative.
RISK MANAGEMENT The process of weighing policy alternatives in the light of the results of risk assessment and, if required, selecting and implementing.
Systematic Review Module 11: Grading Strength of Evidence Interactive Quiz Kathleen N. Lohr, PhD Distinguished Fellow RTI International.
The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.
National Center for Chronic Disease Prevention and Health Promotion
1 Delivering Public Health Messages for Tenancy Sustainment Module 1: Public Health Priorities and the Local Health and Wellbeing Landscape.
Your Health & Wellness Chapter 1 Lesson #1 pg 4-9
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
Recommendation Methods Advisory Committee on Heritable Disorders and Genetic Diseases of Newborns and Children Ned Calonge, M.D., M.P.H.
Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.
Developing evidence-based guidelines at WHO. Evidence-based guidelines at WHO | January 17, |2 |
Expanded focus on Long-term Conditions (including the new Diabetes plan) 2016/17 National Planning workshop 13 Nov 2015.
1 Live like Your Life Depends on it. Advancing the Message Section of Chronic Disease Prevention & Nutrition Services.
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
Georgia Comprehensive Cancer Control Program 3/10/2015 Program Monitoring and Evaluation Activities Short-Term Outcomes Long-Term Outcomes Intermediate.
GDG Meeting Wednesday November 9, :30 – 11:30 am.
Training of Process Facilitators 1- Training of Process Facilitators 5-1.
The US Preventive Services Task Force: Potential Impact on Medicare Coverage Ned Calonge, MD, MPH Chair, USPSTF.
SEPHIG Health Inequalities. Introduction 1.Background – where have we come from 2.Where are we now? 3.The future – where are we going 4.Discussion 2SEPHIG.
1 Health Needs Assessment Workshop Sue Cavanagh Keith Chadwick.
Acute Health Care Perspectives on Homelessness Research Making Data Meaningful April 23, 2015 Ginetta Salvalaggio, MSc, MD, CCFP Assistant Professor, University.
From evidence to Policy: Paediatric guideline development in Kenya Mercy Mulaku.
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
GLOBAL GUIDELINES FOR THE PREVENTION OF SURGICAL SITE INFECTION: An introduction Launched 3 November 2016.
Approach to guideline development
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
Conflicts of interest Major role in development of GRADE
CCC and the CPCRN Garry Lowry, MPH Mary Frost
Choosing Wisely New Zealand
Surveillance. Public Health Approach Surveillance What is the Problem ? Problem Risk Factor Identification : What Is the Cause ? Intervention Evaluation.
Developing a Health Maintenance Schedule
Bell Ringer Open your student workbook and turn to page 57.
GLOBAL GUIDELINES FOR THE PREVENTION OF SURGICAL SITE INFECTION: An introduction Launched 3 November 2016.
Health care decision making
US Preventive Services Task Force. Ann Intern Med 2009;150:
Rationale –Evidence Base
EAST GRADE course 2019 Creating Recommendations
528,000 new cases 266,000 death 90 % of the deaths in LMIC
Evidence Based Practice
Dr Timothy Armstrong Coordinator
Epidemiology Carl Backman 2/26/2004 SOCY C. Backman.
Presentation transcript:

Grading the quality of evidence and the strength of recommendations Equity

For disadvantaged groups are there different 1.Effects? 2.Values? 3.Thresholds for costs? 4.Distributions of disease? 5.Settings? 6.Baseline risks?

Different effects Quality across studies for specific outcomes 1.Are there different effects? Overall quality of evidence across outcomes Balance of benefits and harms Balance of net benefits and costs Recommendations

1. Are there different effects for disadvantaged groups? If there are inconsistent results that can be explained by social inequalities  Different balance sheets for different groups –Tobacco taxation If there is uncertainty about the directness of evidence for disadvantaged groups  Lower quality of evidence –Pneumococcal vaccine

Different values Quality across studies for specific outcomes Overall quality of evidence across outcomes 2.Are there different values? Balance of benefits and harms 2.Are there different values? Balance of net benefits and costs Recommendations

2. Are there differences in the relative importance of the health outcomes for disadvantaged groups? If an outcome is critical for a disadvantaged group and not for others  This may change the overall quality of evidence –If evidence regarding return to work is critical for disadvantaged groups and there is lower quality evidence for this outcome, the overall quality of evidence might be lowered If there are differences in the relative importance of health outcomes  This may change the balance of benefits and harms –Giving more weight to returning more quickly to work may shift the balance in favour of ARVs for HIV

Different thresholds for costs or distributions of disease Quality across studies for specific outcomes Overall quality of evidence across outcomes Balance of benefits and harms Balance of net benefits and costs 3.Are there different thresholds for costs? 4.Are there differences in the distribution of disease? Recommendations

3. Is the cost of an intervention high for disadvantaged groups? If the cost of an intervention is high for disadvantaged groups  This may change the balance of net benefits and costs –Cholesterol screening

4. Are there differences in the distribution of the burden of illness that might affect judgements about whether the intervention is worth the costs? Differences in the distribution of the burden of illness  May change the balance of net benefits and costs –It may be more important to use resources for HIV than for screening for colorectal cancer

Differences in settings or baseline risks Quality across studies for specific outcomes Overall quality of evidence across outcomes Balance of benefits and harms Balance of net benefits and costs Recommendations 5.Are there differences in settings? 6.Are there different baseline risks?

5. Are there factors that would affect the translation of the evidence into practice in disadvantaged settings? If there are important factors that could be expected to modify the size of the expected effects, such as proximity to a hospital or available expertise  This may change a recommendation –Magnesium sulphate

6. Are there differences in baseline risk for disadvantaged groups? If disadvantaged groups are at higher risk  This will increase the benefits –Penicillin for strept throat to prevent Rheumatic fever If there is uncertainty about the baseline risk for disadvantaged groups  This may change a recommendation –BCG for tuberculosis

How do judgements about equity affect recommendations? For disadvantaged groups different 1.Effects –Inconsistant results (tobacco taxation) – explicit value judgment –Uncertainty about directness (pneumococcal vaccine) – recommend evaluation 2.Values –Different values (ARV) – different recommendation 3.Thresholds for costs –Different thresholds (cholesterol screening) – different recommendation 4.Distributions of disease –Different distribution (colorectal cancer screening) – different priorities 5.Settings –Different settings (magnesium sulphate) – different recommendations 6.Baseline risks –Different baseline risks (BCG) – different recommendations 7.People may choose to recommend interventions that are less cost- effective because of equity

Equity should also be considered in formulating questions, implementing recommendations and evaluating the implementation of recommendations Formulating and prioratising questions Quality of studies for specific outcomes Quality across studies for specific outcomes Overall quality of evidence across outcomes Balance of benefits and harms Balance of net benefits and costs Recommendations Implementing recommendations Evaluation